1Q8W image
Entry Detail
PDB ID:
1Q8W
Title:
The Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Rho-kinase Inhibitor Fasudil (HA-1077)
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2003-08-22
Release Date:
2003-12-16
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.29
R-Value Work:
0.21
R-Value Observed:
0.22
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:cAMP-dependent protein kinase, alpha-catalytic subunit
Chain IDs:A
Chain Length:350
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:cAMP-dependent protein kinase inhibitor, alpha form
Chain IDs:B
Chain Length:20
Number of Molecules:1
Biological Source:
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
SEP A SER PHOSPHOSERINE
TPO A THR PHOSPHOTHREONINE
Ligand Molecules
Primary Citation
Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity.
Structure 11 1595 1607 (2003)
PMID: 14656443 DOI: 10.1016/j.str.2003.11.002

Abstact

Protein kinases require strict inactivation to prevent spurious cellular signaling; overactivity can cause cancer or other diseases and necessitates selective inhibition for therapy. Rho-kinase is involved in such processes as tumor invasion, cell adhesion, smooth muscle contraction, and formation of focal adhesion fibers, as revealed using inhibitor Y-27632. Another Rho-kinase inhibitor, HA-1077 or Fasudil, is currently used in the treatment of cerebral vasospasm; the related nanomolar inhibitor H-1152P improves on its selectivity and potency. We have determined the crystal structures of HA-1077, H-1152P, and Y-27632 in complexes with protein kinase A (PKA) as a surrogate kinase to analyze Rho-kinase inhibitor binding properties. Features conserved between PKA and Rho-kinase are involved in the key binding interactions, while a combination of residues at the ATP binding pocket that are unique to Rho-kinase may explain the inhibitors' Rho-kinase selectivity. Further, a second H-1152P binding site potentially points toward PKA regulatory domain interaction modulators.

Legend

Protein

Chemical

Disease

Primary Citation of related structures